Susceptibility of meningococcal strains responsible for two serogroup b outbreaks on U.S. university campuses to serum bactericidal activity elicited by the menb-4c vaccine

Clinical and Vaccine Immunology

Volumn 22, Issue 12, 2015, Pages 1227-1234

  Rossi, Raffaella ^a   Beernink, Peter T ^a   Giuntini, Serena ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NEISSERIAL ADHESIN A ANTIGEN; NEISSERIAL HEPARIN BINDING ANTIGEN; UNCLASSIFIED DRUG; 4CMENB VACCINE; ADHESIN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; NADA PROTEIN, NEISSERIA MENINGITIDIS;

ADULT; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG SENSITIVITY; EPIDEMIC; FEMALE; HUMAN; HUMAN EXPERIMENT; MACACA; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; VACCINATION; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; RHESUS MONKEY; UNITED STATES; UNIVERSITY;

ADHESINS, BACTERIAL; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; HUMANS; MACACA MULATTA; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP B; UNITED STATES; UNIVERSITIES;

EID: 84948135755     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00474-15     Document Type: Article

References (46)

1. Whelan J, Bambini S, Biolchi A, Brunelli B, Robert-Du Ry Van Beest Holle M. 2015. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives. Expert Rev Vaccines 14:713-736. http://dx.doi.org/10.1586/14760584.2015.1004317.
2. McNamara LA, Shumate AM, Johnsen P, MacNeil JR, Patel M, Bhavsar T, Cohn AC, Dinitz-Sklar J, Duffy J, Finnie J, Garon D, Hary R, Hu F, Kamiya H, Kim HJ, Kolligian J, Jr, Neglia J, Oakley J, Wagner J, Wagner K, Wang X, Yu Y, Montana B, Tan C, Izzo R, Clark TA. 2015. First use of a serogroup B meningococcal vaccine in the U.S. in response to a university outbreak. Pediatrics 135:798-804. http://dx.doi.org/10.1542/peds.2014-4015.
3. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B, Cartocci E, Ciucchi L, Di Marcello F, Ferlicca F, Galli B, Luzzi E, Masignani V, Serruto D, Veggi D, Contorni M, Morandi M, Bartalesi A, Cinotti V, Mannucci D, Titta F, Ovidi E, Welsch JA, Granoff D, Rappuoli R, Pizza M. 2006. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103:10834-10839. http://dx.doi.org/10.1073/pnas.0603940103.
4. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30(Suppl 2):B87-B97.
5. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines. Proc Natl Acad Sci U S A 107:19490-19495. http://dx.doi.org/10.1073/pnas.1013758107.
6. Wang X, Shutt KA, Vuong JT, Cohn A, MacNeil J, Schmink S, Plikaytis B, Messonnier NE, Harrison LH, Clark TA, Mayer LW. 2015. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis 211:1887-1894.
7. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197:1053-1061. http://dx.doi.org/10.1086/528994.
8. Costa I, Pajon R, Granoff DM. 2014. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio 5(5):e01625-14. http://dx.doi.org/10.1128/mBio.01625-14.
9. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, Toneatto D, Pollard AJ. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29:e71-e79.
10. Vu DM, Wong TT, Granoff DM. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29:1968-1973. http://dx.doi.org/10.1016/j.vaccine.2010.12.075.
11. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, Oster P, Miller E, Pollard AJ. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51:1127-1137. http://dx.doi.org/10.1086/656741.
12. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ, European MenB Vaccine Study Group. 2012. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 307:573-582.
13. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79:3751-3759. http://dx.doi.org/10.1128/IAI.05182-11.
14. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly crossreactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Sci Rep 2:341.
15. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, Mchugh YE, Moe GR. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160:5028-5036.
16. Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. 2015. Binding of complement factor H (FH) decreases protective anti-FH binding protein antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine. J Infect Dis 212: 784-792.
17. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011. Guide for the care and use of laboratory animals, 8th ed. National Research Council, National Academies Press, Washington, DC. https://grants.nih.gov/grants/olaw/Guide-for-The-Care-And-use-of-laboratory-Animals.pdf.
18. Beernink PT, Giuntini S, Costa I, Lucas AH, Granoff DM. 2015. Functional analysis of the human antibody response to meningococcal Factor H binding protein. mBio 6(3):e00842-15. http://dx.doi.org/10.1128/mBio.00842-15.
19. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186:3606-3614. http://dx.doi.org/10.4049/jimmunol.1003470.
20. Bambini S, De Chiara M, Muzzi A, Mora M, Lucidarme J, Brehony C, Borrow R, Masignani V, Comanducci M, Maiden MC, Rappuoli R, Pizza M, Jolley KA. 2014. Neisseria adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol 21:966-971.
21. Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, Pizza M, Rappuoli R, van de Beek D, van der Ende A, Comanducci M. 2013. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBAover a 50-year period in the Netherlands. PLoS One 8:e65043. http://dx.doi.org/10.1371/journal.pone.0065043.
22. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to crossreactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129. http://dx.doi.org/10.1016/j.vaccine.2009.12.027.
23. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197:789-799. http://dx.doi.org/10.1084/jem.20021911.
24. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200:379-389. http://dx.doi.org/10.1086/600141.
25. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseth SK, Jansen KU, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LW. 2011. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 29:4739-4744. http://dx.doi.org/10.1016/j.vaccine.2011.04.092.
26. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72:2088-2100. http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004.
27. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A, DiMarcello F, Marchi S, van der Ende A, Arico B, Savino S, Scarselli M, Comanducci M, Rappuoli R, Giuliani MM, Pizza M. 2011. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79:970-981. http://dx.doi.org/10.1128/IAI.00891-10.
28. Beernink PT, Granoff DM. 2008. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 76:2568-2575. http://dx.doi.org/10.1128/IAI.00033-08.
29. Konar M, Granoff DM, Beernink PT. 2013. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 208:627-636. http://dx.doi.org/10.1093/infdis/jit239.
30. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. 2011. Meningococcal factorHbinding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 5:e1302. http://dx.doi.org/10.1371/journal.pntd.0001302.
31. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093. http://dx.doi.org/10.1016/j.vaccine.2010.06.083.
32. Lewis LA, Carter M, Ram S. 2012. The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol 188:5063-5072. http://dx.doi.org/10.4049/jimmunol.1103748.
33. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface proteinA(NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6:e1001027. http://dx.doi.org/10.1371/journal.ppat.1001027.
34. Giuntini S, Pajon R, Ram S, Granoff DM. 2015. Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-FHbp bactericidal activity. Infect Immun 83:1536-1545.
35. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio 4(5): e00339-13. http://dx.doi.org/10.1128/mBio.00339-13.
36. Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. 2003. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188:1730-1740. http://dx.doi.org/10.1086/379375.
37. Serruto D, Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M, Santini L, Biolchi A, Seib KL, Giuliani MM, Donnelly JJ, Berti F, Savino S, Scarselli M, Costantino P, Kroll JS, ODwyer C, Qiu J, Plaut AG, Moxon R, Rappuoli R, Pizza M, Arico B. 2010. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A 107:3770-3775. http://dx.doi.org/10.1073/pnas.0915162107.
38. Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, Rappuoli R, Pizza M, Donnelly J. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030. http://dx.doi.org/10.1016/j.vaccine.2010.05.014.
39. MacNeil J. 2015. Considerations for use of serogroup B meningococcal (MenB) vaccines in adolescents. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/mening-03-macneil.pdf.
40. Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK. 2014. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol 14:111. http://dx.doi.org/10.1186/1471-2180-14-111.
41. Krzov P, Musilek M, Vackov Z, Kozkov J, Claus H, Vogel U, Medini D. 2014. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol 63:103-106.
42. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R. 2013. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416-425. http://dx.doi.org/10.1016/S1473-3099(13)70006-9.
43. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R, Members of the Canadian Immunization Monitoring Program, Active (IMPACT). 2013. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 32:124-130. http://dx.doi.org/10.1016/j.vaccine.2013.03.063.
44. Vogel U, Stefanelli P, Vazquez J, Taha MK, Claus H, Donnelly J. 2012. The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines. Vaccine 30(Suppl 2):B73-B77.
45. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D. 2013. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31:4968-4974. http://dx.doi.org/10.1016/j.vaccine.2013.08.006.
46. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, Urwin R, Zhang Q, Zhou J, Zurth K, Caugant DA, Feavers IM, Achtman M, Spratt BG. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95:3140-3145. http://dx.doi.org/10.1073/pnas.95.6 .3140.